combination therapy

1:44
Lessons learned from the CLL CLARITY study and ongoing follow-up
Talha Munir
0:40
Approval of Dvd for myeloma at first relapse in the UK: impacts on care
Tanya Burton
2:27
Treatment challenges in myeloma
Yi Lin
4:48
The quality control measures recommended within the JACIE model
Eoin McGrath
1:24
The JACIE model for centers administering CAR T-cell therapy
Eoin McGrath
3:21
EMA initiatives on registries
Eoin McGrath
4:55
Checkpoint inhibitor combination approaches for AML/MDS: an update
Naval Daver
1:29
Risk-adapted therapy of AML
Christoph Röllig
2:16
BCL-2 targeting in AML: updates
Marina Konopleva
2:26
Combining BCL-2 and MCL-1 inhibitors in AML
Andrew Wei
3:33
Targeting BCL-2 in older AML: novel venetoclax combinations
Andrew Wei
5:24
Translating epigenetic therapy to the clinic: rational combinations
Ari Melnick
0:55
CAR-T and ibrutinib in combination: a promising treatment for CLL
Lydia Scarfò
2:45
Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
2:38
MPN updates: personalized prognostication, novel treatments & more
Ruben Mesa
4:09
iFCG for IGHV-mutated CLL in the frontline
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals © ®